Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
- Conditions
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT03217838
- Locations
- 🇦🇺
Research Site, Melbourne, Australia
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT03214562
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT03194932
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Lucille Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 69
- Registration Number
- NCT03181126
- Locations
- 🇺🇸
City of Hope /ID# 169029, Duarte, California, United States
🇺🇸LPCH Stanford /ID# 163337, Palo Alto, California, United States
🇺🇸University of Chicago /ID# 163369, Chicago, Illinois, United States
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03135262
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT03128879
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Expanded Access to Venetoclax
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03123029
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT03113643
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 352
- Registration Number
- NCT03112174
- Locations
- 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 153
- Registration Number
- NCT03082209
- Locations
- 🇺🇸
Millennium Oncology /ID# 214981, Houston, Texas, United States
🇺🇸Yale University /ID# 158029, New Haven, Connecticut, United States
🇺🇸The University of Chicago Medical Center /ID# 158030, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.